Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 13/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863542 | 0.90 | PDK1 (0.48) | LTA4HESR1ESR2PDK1PDK2 | |
| SCHEMBL5863941 | 0.86 | HTT (0.49) | LTA4HESR1ESR2PDK1PDK2 | |
| SCHEMBL5863430 | 0.84 | HTT (0.55) | LTA4HESR1ESR2PDK1PDK2 | |
| SCHEMBL5863880 | 0.83 | ESR1 (0.47) | ESR1ESR2PDK1PDK2PDK3 | |
| SCHEMBL2112716 | 0.81 | LTA4H (0.64) | LTA4HESR1ESR2PSMB1PSMB5 | |
| SCHEMBL5863730 | 0.81 | ESR1 (0.50) | LTA4HESR1ESR2HTTKDM4E | |
| SCHEMBL2115656 | 0.80 | LTA4H (0.62) | LTA4HESR1ESR2PSMB1PSMB5 | |
| SCHEMBL11873434 | 0.78 | LTA4H (0.68) | LTA4HESR1ESR2PSMB1PSMB5 | |
| SCHEMBL11879052 | 0.77 | LTA4H (0.67) | LTA4HESR1PSMB1PSMB5HTT | |
| SCHEMBL2115067 | 0.77 | LTA4H (0.67) | LTA4HESR1PSMB1PSMB5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | LTA4H 1687/4885ESR1 4/4885ESR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.